Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cyclacel Pharma (CYCC) Tops Q3 EPS by 8c
November 11, 2020 4:36 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.47), $0.08 better than the analyst estimate of ($0.55).
We continue to execute on our clinical development plan for fadraciclib and CYC140 in both liquid and solid cancers, said Spiro Rombotis, President and Chief Executive Officer. The recent ENA presentation... More
